The diagnostic and clinicopathological value of trefoil factor 3 in patients with gastric cancer: a systematic review and meta-analysis

References

• Aikou, S., et al., 2011. Tests for serum levels of trefoil factor family proteins can improve gastric cancer screening. Gastroenterology, 141 (3), 837–845.
   PubMed Web of Science ®Google Scholar
• Bray, F., et al., 2018. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians, 68 (6), 394–424.
   PubMed Web of Science ®Google Scholar
• Chen, Y.H., et al., 2000. Transcription factor NF-kappaB signals antianoikic function of trefoil factor 3 on intestinal epithelial cells. Biochemical and biophysical research communications, 274 (3), 576–582.
   PubMed Web of Science ®Google Scholar
• Choi, B., et al., 2017. Plasma expression of the intestinal metaplasia markers CDH17 and TFF3 in patients with gastric cancer. Cancer biomarkers: section A of disease markers, 19 (3), 231–239.
   PubMed Web of Science ®Google Scholar
• Dhar, D.K., et al., 2005. Expression of trefoil factor family members correlates with patient prognosis and neoangiogenesis. Clinical cancer research, 11 (18), 6472–6478.
   PubMed Web of Science ®Google Scholar
• Ding, A., et al., 2013. Impact of NPM, TFF3 and TACC1 on the prognosis of patients with primary gastric cancer. PLoS one, 8 (12), e82136.
   PubMed Web of Science ®Google Scholar
• Gao, Y.D., Qu, Y.W., and Liu, H.F., 2018. Comparison of diagnostic efficacy between CLE, tissue sampling, and CLE combined with tissue sampling for undetermined pancreaticobiliary strictures: a meta-analysis. Scandinavian journal of gastroenterology, 53 (4), 482–489.
   PubMed Web of Science ®Google Scholar
• Grivennikov, S.I., Greten, F.R., and Karin, M., 2010. Immunity, inflammation, and cancer. Cell, 140 (6), 883–899.
   PubMed Web of Science ®Google Scholar
• Gu, J., et al., 2015. TFF3 and HER2 expression and their correlation with survival in gastric cancer. Tumour biology: the journal of the international society for oncodevelopmental biology and medicine, 36 (4), 3001–3007.
   PubMedGoogle Scholar
• Guleng, B., et al., 2012. TFF3 mediated induction of VEGF via hypoxia in human gastric cancer SGC-7901 cells. Molecular biology reports, 39 (4), 4127–4134.
   PubMed Web of Science ®Google Scholar
• Hamashima, C., et al., 2008. The Japanese guidelines for gastric cancer screening. Japanese journal of clinical oncology, 38 (4), 259–267.
   PubMed Web of Science ®Google Scholar
• Higgins, J.P., et al., 2003. Measuring inconsistency in meta-analyses. BMJ, 327 (7414), 557–560.
   PubMed Web of Science ®Google Scholar
• Hoffmann, W., 2015. TFF2, a MUC6-binding lectin stabilizing the gastric mucus barrier and more (Review). International journal of oncology, 47 (3), 806–816.
   PubMed Web of Science ®Google Scholar
• Hoffmann, W., Jagla, W., and Wiede, A., 2001. Molecular medicine of TFF-peptides: from gut to brain. Histology and histopathology, 16 (1), 319–334.
   PubMed Web of Science ®Google Scholar
• Huang, Z., et al., 2014. Serum trefoil factor 3 is a promising non-invasive biomarker for gastric cancer screening: a monocentric cohort study in China. BMC gastroenterology, 14, 74.
   PubMed Web of Science ®Google Scholar
• Im, S., et al., 2013. Reduced expression of TFF1 and increased expression of TFF3 in gastric cancer: correlation with clinicopathological parameters and prognosis. International journal of medical sciences, 10 (2), 133–140.
   PubMed Web of Science ®Google Scholar
• Inagaki-Ohara, K., et al., 2014. Enhancement of leptin receptor signaling by SOCS3 deficiency induces development of gastric tumors in mice. Oncogene, 33 (1), 74–84.
   PubMed Web of Science ®Google Scholar
• Jackson, D., White, I.R., and Thompson, S.G., 2010. Extending DerSimonian and Laird’s methodology to perform multivariate random effects meta-analyses. Statistics in medicine, 29 (12), 1282–1297.
   PubMed Web of Science ®Google Scholar
• Kaise, M., et al., 2011. The combination of serum trefoil factor 3 and pepsinogen testing is a valid non-endoscopic biomarker for predicting the presence of gastric cancer: a new marker for gastric cancer risk. Journal of gastroenterology, 46 (6), 736–745.
   PubMed Web of Science ®Google Scholar
• Katoh, M., 2016. Trefoil factors and human gastric cancer (review). International journal of molecular medicine, 38 (1), 3–9.
   PubMed Web of Science ®Google Scholar
• Kjellev, S., 2009. The trefoil factor family - small peptides with multiple functionalities. Cellular and molecular life sciences, 66 (8), 1350–1369.
   PubMed Web of Science ®Google Scholar
• Lee, H.S., et al., 2018. Screening biomarker as an alternative to endoscopy for the detection of early gastric cancer: the combination of serum trefoil factor family 3 and pepsinogen. Gastroenterology research and practice, 2018, 1024074.
   PubMed Web of Science ®Google Scholar
• Lee, J.Y., et al., 2017. Comparison of serum trefoil factor 3 with the pepsinogen test for the screening of diffuse-type gastric cancer. Clinical and experimental medicine, 17 (3), 403–410.
   PubMed Web of Science ®Google Scholar
• Li, Y., et al., 2014. Prognostic significance of the co-expression of nucleophosmin and trefoil factor 3 in postoperative gastric cancer patients. Molecular and clinical oncology, 2 (6), 1055–1061.
   PubMedGoogle Scholar
• Liu, G., et al., 2017. Clinicopathological and prognostic significance of TFF3 immunohistochemical expression in gastric cancer: a meta-analysis. International journal of clinical and experimental medicine, 10 (7), 11179–11186.
   Web of Science ®Google Scholar
• Lu, Y.Y., et al., 2009. Correlation of trefoil factor 3 expression in gastric carcinoma, precancerous lesions, gastric adenoma with angiogenesis. World Chinese Journal of Digestology, 17 (36), 3688–3692.
   Google Scholar
• Meng, J.R., et al., 2013. TFF3 and survivin expressions associate with a lower survival rate in gastric cancer. Clinical and experimental medicine, 13 (4), 297–303.
   PubMed Web of Science ®Google Scholar
• Meyer, Z.B.D., et al., 2004. Molecular mechanisms involved in TFF3 peptide-mediated modulation of the E-cadherin/catenin cell adhesion complex. Peptides, 25 (5), 873–883.
   PubMed Web of Science ®Google Scholar
• Miki, K., et al., 2009. Long-term results of gastric cancer screening using the serum pepsinogen test method among an asymptomatic middle-aged Japanese population. Digestive endoscopy, 21 (2), 78–81.
   PubMed Web of Science ®Google Scholar
• Muskett, F.W., et al., 2003. Solution structure of the disulfide-linked dimer of human intestinal trefoil factor (TFF3): the intermolecular orientation and interactions are markedly different from those of other dimeric trefoil proteins. Biochemistry, 42 (51), 15139–15147.
   PubMed Web of Science ®Google Scholar
• Ren, J., et al., 2017. The diagnostic and prognostic values of microRNA-21 in patients with gastric cancer: a meta-analysis. European review for medical and pharmacological sciences, 21 (1), 120–130.
   PubMed Web of Science ®Google Scholar
• Rivat, C., et al., 2005. Implication of STAT3 signaling in human colonic cancer cells during intestinal trefoil factor 3 (TFF3) – and vascular endothelial growth factor-mediated cellular invasion and tumor growth. Cancer research, 65 (1), 195–202.
   PubMed Web of Science ®Google Scholar
• Schuetz, G.M., et al., 2010. Quality of diagnostic accuracy studies: QUADAS (Quality Assessment of Diagnostic Accuracy Studies Included in Systematic Reviews). RoFo: Fortschritte auf dem gebiete der rontgenstrahlen und der nuklearmedizin, 182 (11), 939–942.
   PubMedGoogle Scholar
• Soleyman-Jahi, S., et al., 2017. Prognostic significance of preoperative and postoperative plasma levels of ghrelin in gastric cancer: 3-year survival study. Clin transl gastroenterol, 8 (1), e209.
   PubMed Web of Science ®Google Scholar
• Suzuki, T., et al., 2019. Early gastric cancer diagnostic ability of ultrathin endoscope loaded with laser light source. World journal of gastroenterology, 25 (11), 1378–1386.
   PubMed Web of Science ®Google Scholar
• Taniguchi, Y., et al., 2018. Prognostic value of trefoil factor 3 expression in patients with gastric cancer. World journal of surgery, 42 (12), 3997–4004.
   PubMed Web of Science ®Google Scholar
• Thrift, A.P. and El-Serag, H.B., 2020. Burden of gastric cancer. Clinical gastroenterology and hepatology, 18 (3), 534–542.
   PubMed Web of Science ®Google Scholar
• Wang, J., et al., 2014. Altered expression of hypoxia-inducible factor-1α (HIF-1α) and its regulatory genes in gastric cancer tissues. PLoS One, 9 (6), e99835.
   PubMed Web of Science ®Google Scholar
• Wei, H., et al., 2019. The diagnostic value of circulating microRNAs as a biomarker for gastric cancer: a meta-analysis. Oncology reports, 41 (1), 87–102.
   PubMed Web of Science ®Google Scholar
• Xu, C.C., et al., 2013. Significance of TFF3 protein and Her-2/neu status in patients with gastric adenocarcinoma. Pathology, research and practice, 209 (8), 479–485.
   PubMed Web of Science ®Google Scholar
• Yamachika, T., et al., 2002. Intestinal trefoil factor: a marker of poor prognosis in gastric carcinoma. Clinical cancer research, 8 (5), 1092–1099.
   PubMed Web of Science ®Google Scholar
• Zhang, X., et al., 2016. Clinical research of serum trefoil factor 3 expression in gastric cancer. Chinese journal of gastroenterology, 21 (2), 93–97.
   Google Scholar